WASHINGTON — The Trump administration’s Tuesday agreement on a new trade deal with Canada and Mexico is very bad news for the drug industry.

The newly unveiled deal, commonly known as USMCA, will not have any protection for high-tech biologic drugs, which are made from living cells. That’s a huge break from the first version of the deal, which was unveiled in late September 2018 and included 10 years of exclusivity protection for these drugs. That provision was removed as part of an effort to appease House Democrats, who must approve the trade deal before it can be ratified.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If the middlemen (PBM’s) like this deal WATCH OUT !!! They’re gonna fleece
    America more than they ever did before !!!!!!

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy